Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth

Open Ended Schemes(Equity Scheme - Sectoral/ Thematic)Very High RiskISIN INF209KB1O25

NAV · 06-Jul-2026

₹39.4100

+7.52%

+14.87%

1Y (CAGR)

+16.14%

3Y (CAGR)

+24.59%

5Y (CAGR)

+14.70%

Since inception (CAGR)

+21.59%

NAV history

hover for values

Risk & SIP analytics

Q1 · TOP · 3Y in category

Volatility (3y)

12.97%

Downside dev (3y)

8.78%

Max drawdown (3y)

-15.9%

Sharpe (3y)

1.39

SIP XIRR (3y)

+17.74%

SIP XIRR (5y)

+19.79%

Calendar-year returns

2020 +56.6%2021 +21.4%2022 -11.3%2023 +39.6%2024 +37.7%2025 -3.1%

Fund facts

Fund managerDhaval Shah

AUM₹9,503 Cr

Expense ratio0.84% · 2026-05-31

TER · AMFI officialDirect 1.01% · Regular 2.28% (2026-06-30)

Launch date20-Jun-2019

Plan typeOpen Ended · Equity

Min lumpsum₹1,000

Min SIP₹100

Lock-inNone

Volatility15.20

AMCAditya Birla Sun Life AMC Limited

Objective · The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.

scheme documents ↗